VYNE Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VYNE research report →
About the company
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris.
- CEO
- David T. Domzalski
- IPO
- 2018
- Employees
- 13
- HQ
- Bridgewater, NJ, US
Price Chart
- Market Cap
- $11.33M
- P/E
- -1.41
- P/S
- 24.96
- P/B
- 1.18
- EV/EBITDA
- 0.61
- Div Yield
- 0.00%
- Gross Margin
- 98.68%
- Op Margin
- -5367.62%
- Net Margin
- -4726.21%
- ROE
- -69.57%
- ROIC
- -98.91%
- Revenue
- $570.00K · 13.77%
- Net Income
- $-26,483,000 · 33.52%
- EPS
- $-0.62 · 34.04%
- Op Income
- $-29,749,000
- FCF YoY
- 2.83%
- 52W High
- $1.59
- 52W Low
- $0.28
- 50D MA
- $0.66
- 200D MA
- $0.53
- Beta
- 2.01
- Avg Volume
- 169.18K
Get TickerSpark's AI analysis on VYNE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Zeronda Tyler | other | 3,464 |
| Jun 30, 26 | Stuart Iain | other | 2,370 |
| Jun 30, 26 | Harsch Mutya | other | 3,464 |
| Jun 30, 26 | Domzalski David | other | 12,214 |
| May 29, 26 | Domzalski David | other | 30,791 |
| Mar 31, 26 | Zeronda Tyler | other | 4,007 |
| Mar 31, 26 | Stuart Iain | other | 2,876 |
| Mar 31, 26 | Harsch Mutya | other | 4,007 |
| Mar 31, 26 | Domzalski David | other | 14,232 |
| Dec 31, 25 | Domzalski David | other | 12,684 |
Our VYNE coverage
Recent articles, reports, and earnings notes.
No research on VYNE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VYNE report →Similar companies
Peers in the same neighborhood.